NB002
/ Neologics Biosci
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
June 29, 2023
A Dose Escalation and Expansion Study of NB002 in Participants With Advanced or Metastatic Solid Tumors
(clinicaltrials.gov)
- P1a/1b | N=30 | Not yet recruiting | Sponsor: Suzhou Neologics Bioscience Co., Ltd.
Metastases • New P1 trial • Gastrointestinal Cancer • Oncology • Solid Tumor • HAVCR2
March 14, 2023
NB002, a novel therapeutic antibody targeting unique epitope on TIM-3 presenting potent antitumor activity
(AACR 2023)
- "These data could potentially explain novel features of NB002, restoring both acquired and innate immunity which could lead cold tumor to hot tumor.In summary, these data showed that NB002 is a potent anti-TIM-3 antibody with pre-clinical properties. A phase 1 study is planned and patients with advanced metastatic solid tumors will be recruited."
IO biomarker • Oncology • Solid Tumor • CTLA4 • HAVCR2 • IFNG • PD-1
1 to 2
Of
2
Go to page
1